# Metastatic Urothelial Cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/metastatic-urothelial-cancer

> 2 upcoming FDA catalysts in metastatic Urothelial Cancer: sacituzumab govitecan-hziy (GILD) on April 2030 (primary completion); sacituzumab govitecan-hziy (GILD) on Apr to Jul 2030 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 2030 | [Sacituzumab govitecan-hziy primary completion](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Metastatic Urothelial Cancer | scheduled | "NCT03547973 (Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-04 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03547973)) |
| Apr to Jul 2030 | [Sacituzumab govitecan-hziy topline data readout](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Metastatic Urothelial Cancer | scheduled | "NCT03547973 (Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-04 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03547973)) |

## Drugs

- [Sacituzumab govitecan-hziy](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) (GILD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/metastatic-urothelial-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Metastatic Urothelial Cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/metastatic-urothelial-cancer

```bibtex
@misc{secapidev_indications_metastatic_urothelial_cancer_20261116,
  title        = {Metastatic Urothelial Cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/metastatic-urothelial-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_metastatic_urothelial_cancer_20261116","title":"Metastatic Urothelial Cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/metastatic-urothelial-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
